ADMA BIOLOGICS INC (ADMA)
US0008991046 - Common Stock
Taking everything into account, ADMA scores 6 out of 10 in our fundamental rating. ADMA was compared to 565 industry peers in the Biotechnology industry. While ADMA has a great health rating, its profitability is only average at the moment. ADMA is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings could make ADMA a good candidate for growth investing.
1. Profitability
1.1 Basic Checks
In the past year ADMA was profitable.
In the past year ADMA had a positive cash flow from operations.
In the past 5 years ADMA always reported negative net income.
ADMA had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of ADMA (17.44%) is better than 98.22% of its industry peers.
ADMA's Return On Equity of 29.38% is amongst the best of the industry. ADMA outperforms 98.04% of its industry peers.
With an excellent Return On Invested Capital value of 26.25%, ADMA belongs to the best of the industry, outperforming 99.11% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.44% | ||
| ROE | 29.38% | ||
| ROIC | 26.25% |
ROA(3y)-17.8%
ROA(5y)-25.57%
ROE(3y)-38.32%
ROE(5y)-77.03%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 17.80%, ADMA belongs to the best of the industry, outperforming 96.79% of the companies in the same industry.
ADMA has a better Operating Margin (30.01%) than 98.40% of its industry peers.
ADMA has a better Gross Margin (48.93%) than 77.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 30.01% | ||
| PM (TTM) | 17.8% | ||
| GM | 48.93% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), ADMA is creating value.
Compared to 1 year ago, ADMA has more shares outstanding
The number of shares outstanding for ADMA has been increased compared to 5 years ago.
ADMA has a better debt/assets ratio than last year.
2.2 Solvency
ADMA has an Altman-Z score of 20.38. This indicates that ADMA is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 20.38, ADMA belongs to the top of the industry, outperforming 93.23% of the companies in the same industry.
The Debt to FCF ratio of ADMA is 1.29, which is an excellent value as it means it would take ADMA, only 1.29 years of fcf income to pay off all of its debts.
ADMA has a better Debt to FCF ratio (1.29) than 95.72% of its industry peers.
A Debt/Equity ratio of 0.44 indicates that ADMA is not too dependend on debt financing.
The Debt to Equity ratio of ADMA (0.44) is worse than 72.73% of its industry peers.
Although ADMA does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.44 | ||
| Debt/FCF | 1.29 | ||
| Altman-Z | 20.38 |
ROIC/WACC2.49
WACC10.54%
2.3 Liquidity
ADMA has a Current Ratio of 7.09. This indicates that ADMA is financially healthy and has no problem in meeting its short term obligations.
ADMA has a Current ratio of 7.09. This is in the better half of the industry: ADMA outperforms 68.45% of its industry peers.
A Quick Ratio of 3.26 indicates that ADMA has no problem at all paying its short term obligations.
With a Quick ratio value of 3.26, ADMA perfoms like the industry average, outperforming 41.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.09 | ||
| Quick Ratio | 3.26 |
3. Growth
3.1 Past
ADMA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 354.55%, which is quite impressive.
Looking at the last year, ADMA shows a very strong growth in Revenue. The Revenue has grown by 63.40%.
Measured over the past years, ADMA shows a very strong growth in Revenue. The Revenue has been growing by 72.31% on average per year.
EPS 1Y (TTM)354.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1400%
Revenue 1Y (TTM)63.4%
Revenue growth 3Y82.9%
Revenue growth 5Y72.31%
Sales Q2Q%78.13%
3.2 Future
The Earnings Per Share is expected to grow by 48.00% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 16.23% on average over the next years. This is quite good.
EPS Next Y478.18%
EPS Next 2Y167.93%
EPS Next 3Y98.21%
EPS Next 5Y48%
Revenue Next Year58.35%
Revenue Next 2Y33.82%
Revenue Next 3Y25.98%
Revenue Next 5Y16.23%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
ADMA is valuated quite expensively with a Price/Earnings ratio of 76.07.
Compared to the rest of the industry, the Price/Earnings ratio of ADMA indicates a rather cheap valuation: ADMA is cheaper than 93.94% of the companies listed in the same industry.
ADMA's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 28.96.
A Price/Forward Earnings ratio of 31.64 indicates a quite expensive valuation of ADMA.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ADMA indicates a rather cheap valuation: ADMA is cheaper than 93.40% of the companies listed in the same industry.
ADMA's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 23.82.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 76.07 | ||
| Fwd PE | 31.64 |
4.2 Price Multiples
ADMA's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ADMA is cheaper than 94.47% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, ADMA is valued cheaply inside the industry as 94.65% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 63.88 | ||
| EV/EBITDA | 41.15 |
4.3 Compensation for Growth
ADMA's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ADMA's earnings are expected to grow with 98.21% in the coming years.
PEG (NY)0.16
PEG (5Y)N/A
EPS Next 2Y167.93%
EPS Next 3Y98.21%
5. Dividend
5.1 Amount
ADMA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ADMA BIOLOGICS INC
NASDAQ:ADMA (11/21/2024, 8:10:49 PM)
After market: 21.4999 +0.2 (+0.94%)21.3
-0.07 (-0.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap5.04B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 76.07 | ||
| Fwd PE | 31.64 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.16
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.44% | ||
| ROE | 29.38% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 30.01% | ||
| PM (TTM) | 17.8% | ||
| GM | 48.93% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.98
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.44 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 7.09 | ||
| Quick Ratio | 3.26 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)354.55%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y478.18%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)63.4%
Revenue growth 3Y82.9%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y